KALA BIO, Inc.

KALA ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2016 FY2015
Revenue $0 $45.0K
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $25.0M $11.4M
SG&A Expense $7.6M $4.6M
Operating Income $-32.7M $-15.9M
Operating Margin -35,435.6%
Interest Expense $767.0K $604.0K
Pretax Income
Income Tax Expense $0
Net Income $-33.2M $-16.7M
Net Margin -37,071.1%
EPS (Basic) $-14.04 $-7.45
EPS (Diluted) $-14.04 $-7.45
Shares Outstanding (Basic) 2.4M
Shares Outstanding (Diluted) 2.4M
Dividends Per Share
← Newer Page 2 of 2 Older →